Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer.

Jian ZhangDongmei Ji Weina ShenQin XiaoYajia GuJoyce O'ShaughnessyXi-Chun Hu

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

ARX788 demonstrated a manageable safety profile with promising preliminary signs of activity in patients with HER2-positive MBC who progressed on prior anti-HER2 therapies.

Keyphrases

metastatic breast cancer
clinical trial
study protocol
phase iii
phase ii
randomized controlled trial
cancer therapy
combination therapy
drug delivery
open label